to evaluate the efficacy of intravenous etidronate disodium ( etidronate ) in controlling hypercalcemia of malignancy , 20 patients with known malignant disease and hypercalcemia were randomly assigned on a two-to-one basis to receive etidronate , 7.5 mg/kg of body weight , or placebo for three to five days .
C0020437
hypercalcemia
C0086268
etidronate